Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.

@article{Samineni2012SteadystatePI,
  title={Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.},
  author={Divya Samineni and Pankaj B. Desai and Larry Sallans and Carl J. Fichtenbaum},
  journal={Journal of clinical pharmacology},
  year={2012},
  volume={52 6},
  pages={
          922-31
        }
}
HIV-1 protease inhibitors often cause dyslipidemia, necessitating the use of lipid-lowering agents such as rosuvastatin. However, when given concomitantly, these therapeutic agents often exhibit adverse drug interactions. In this study (phase I open-label trial, n = 12 HIV-1 seronegative participants), the authors assessed the drug interactions between darunavir/ritonavir given in combination with rosuvastatin. Participants were randomized to receive rosuvastatin (10 mg/day) or darunavir… CONTINUE READING
Highly Cited
This paper has 23 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Managing drug interactions in HIV-infected adults with comorbid illness.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne • 2015